

CORRECTION


Correction: HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies

Celia C. LaBranche, Andrew T. McGuire, Matthew D. Gray, Shay Behrens, Xuejun Chen, Tongqing Zhou, Quentin J. Sattentau, James Peacock, Amanda Eaton, Kelli Greene, Hongmei Gao, Haili Tang, Lautaro G. Perez, Kevin O. Saunders, Peter D. Kwong, John R. Mascola, Barton F. Haynes, Leonidas Stamatatos, David C. Montefiori

Peter D. Kwong and Xuejun Chen are not included in the author byline. Xuejun Chen should be listed as the fifth author and Peter D. Kwong should be listed as the fifteenth author. Both are affiliated with Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA. The contributions of these authors are as follows: Investigation, Resources.

Reference

1. LaBranche CC, McGuire AT, Gray MD, Behrens S, Zhou T, Sattentau QJ, et al. (2018) HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies. *PLoS Pathog* 14(11): e1007431. <https://doi.org/10.1371/journal.ppat.1007431> PMID: 30395637



OPEN ACCESS

Citation: LaBranche CC, McGuire AT, Gray MD, Behrens S, Chen X, Zhou T, et al. (2019) Correction: HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies. *PLoS Pathog* 15(3): e1007646. <https://doi.org/10.1371/journal.ppat.1007646>

Published: March 26, 2019

Copyright: © 2019 LaBranche et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.